5-fluorouracil + cisplatin + dexrazoxane + doxorubicin + vincristine

This is a combination chemotherapy regimen consisting of five agents: 5-fluorouracil, cisplatin, dexrazoxane, doxorubicin, and vincristine. Each component has a distinct mechanism of action targeting cancer cells: - 5-fluorouracil is an antimetabolite that inhibits thymidylate synthase, blocking DNA synthesis. - Cisplatin is a platinum-based compound that forms DNA crosslinks and induces apoptosis. - Dexrazoxane acts as a cardioprotective agent by chelating iron and reducing free radical formation; it is often used to mitigate the cardiotoxicity associated with anthracyclines like doxorubicin. - Doxorubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage. - Vincristine disrupts microtubule formation during mitosis. This multi-agent regimen aims to maximize anti-tumor efficacy by combining drugs with complementary mechanisms. Such regimens are primarily used in pediatric oncology for conditions like hepatoblastoma or other solid tumors where aggressive multi-drug therapy may be indicated[1][2][6]. The addition of dexrazoxane specifically helps reduce the risk of cardiac toxicity from doxorubicin.